Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimer's disease and mild cognitive impairment

Experimental Gerontology

Volumn 45, Issue 1, 2010, Pages 41-46

  Olson, Lars ^a   Humpel, Christian ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Alzheimer; Blood; Cerebrospinal fluid; Diagnosis; Plasma

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ANGIOPOIETIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CHEMOKINE; COLONY STIMULATING FACTOR; COLONY STIMULATING FACTOR 1; CYTOKINE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERLEUKIN 3; NERVE GROWTH FACTOR; PROGRANULIN; SCATTER FACTOR; SOMATOMEDIN; TAU PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ALZHEIMER DISEASE; BLOOD CELL; CELL STIMULATION; CLINICAL FEATURE; CYTOKINE RELEASE; DEGENERATIVE DISEASE; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; HUMAN; MILD COGNITIVE IMPAIRMENT; NERVOUS SYSTEM INFLAMMATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; SENSITIVITY AND SPECIFICITY; SHORT SURVEY;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CHEMOKINES; COGNITION DISORDERS; CYTOKINES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; SEVERITY OF ILLNESS INDEX;

EID: 71849101413     PISSN: 05315565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exger.2009.10.011     Document Type: Short Survey

References (60)

1. Aguado-Llera D., Arilla-Ferreiro E., Campos-Barros A., Puebla-Jimenez L., and Barrios V. Protective effects of insulin-like growth factor-I on the somatostatinergic system in the temporal cortex of beta-amyloid-treated rats. J. Neurochem. 92 (2005) 607-615
2. Angelopoulos P., Agouridaki H., Vaiopoulos H., Siskou E., Doutsou K., Costa V., and Baloyiannis S.I. Cytokines in Alzheimer's disease and vascular dementia. Int. J. Neurosci. 118 12 (2008) 1659-1672
3. Baranowska-Bik A., Bik W., Wolinska-Witort E., Martynska L., Chmielowska M., Barcikowska M., and Baranowska B. Plasma beta amyloid and cytokine profile in women with Alzheimer's disease. Neuro. Endocrinol. Lett. 29 1 (2008) 75-79
4. Barde Y.A. The nerve growth factor family. Prog. Growth Factor Res. 2 (1990) 237-248
5. Bergman M., Salman H., Beloosesky Y., Djaldetti M., and Bessler H. Are peripheral blood cells from patients with Alzheimer disease more sensitive to apoptotic stimuli?. Alzheimer Dis. Assoc. Disord. 16 3 (2002) 156-160
6. Bermejo P., Martin-Aragon S., Benedi J., Susin C., Felici E., Gil P., Ribera J.M., and Villar A.M. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. Immunol. Lett. 117 2 (2008) 198-202
7. Blasko I., Lederer W., Oberbauer H., Walch T., Kemmler G., Hinterhuber H., Marksteiner J., and Humpel C. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement. Geriatr. Cogn. Disord. 21 (2006) 9-15
8. Bruunsgaard H., Andersen-Ranberg K., Jeune B., Pedersen A.N., Skinhoj P., and Pedersen B.K. A high plasma concentration of TNF-alpha is associated with dementia incentenarians. J. Gerontol. A. Biol. Sci. Med. Sci. 54 7 (1999) M357-M364
9. Cantara S., Ziche M., and Donnini S. Opposite effects of beta amyloid on endothelial cell survival: role of fibroblast growth factor2 (FGF-2). Pharmacol. Rep. 57 (2005) 138-143
10. Carro E., Trejo J.L., Gomez-Isla T., LeRoith D., and Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat. Med. 8 (2002) 1390-1397
11. De Servi B., La Porta C.A., Bontempelli M., and Comolli R. Decrease of TGF-beta1 plasma levels and increase of nitric oxide synthaseactivity in leukocytes as potential biomarkers of Alzheimer's disease. Exp. Gerontol. 37 6 (2002) 813-821
12. Dik M.G., Jonker C., Hack C.E., Smit J.H., Comijs H.C., and Eikelenboom P. Serum inflammatory proteins and cognitive decline in older persons. Neurology 64 8 (2005) 1371-1377
13. Fahnestock M., Michalski B., Xu B., and Coughlin M.D. The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Mol. Cell. Neurosci. 18 (2001) 210-220
14. Franceschi C., Valensin S., Bonafe M., et al. The network and the remodeling theories of aging, historical background and new perspectives. Exp. Gerontol. 35 (2000) 879-896
15. Fukumura D., Xu L., Chen Y., Gohongi T., Seed B., and Jain R.K. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumor in vivo. Cancer Res. 61 (2001) 6020-6024
16. Galloway E.M., Woo N.H., and Lu B. Persistent neural activity in the prefrontal cortex: a mechanism by which BDNF regulates working memory?. Prog. Brain Res. 169 (2008) 251-266
17. Galimberti D., Venturelli E., Fenoglio C., Guidi I., Villa C., Bergamaschini L., Cortini F., Scalabrini D., Baron P., Vergani C., Bresolin N., and Scarpini E. Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration. J. Neurol. 255 4 (2008) 539-544
18. Galimberti D., Fenoglio C., Lovati C., Venturelli E., Guidi I., Corra B., Scalabrini D., Clerici F., Mariani C., Bresolin N., and Scarpini E. Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. Neurobiol. Aging 27 12 (2006) 1763-1768 (Epub 2005 Nov 22)
19. Gianni D., Zambrano N., Bimonte M., et al. Platelet-derived growth factor induces the beta-gamma-secretase-mediated cleavage of Alzheimer's amyloid precursor protein through a Src-Rac-dependent pathway. J. Biol. Chem. 278 (2003) 9290-9297
20. Gonzalez-Scarano F., and Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu. Rev. Neurosci. 22 (1999) 219-240
21. Grammas P., and Ovase R. Cerebrovascular transforming growth factor-beta contributes to inflammation in the Alzheimer's disease brain. Am. J. Pathol. 160 (2002) 1583-1587
22. Grundstrom E., Lindholm D., Johansson A., Blennow K., and Askmark H. GDNF but not BDNF is increased in cerebrospinal fluid in amyotrophic lateral sclerosis. Neuroreport 11 (2000) 1781-1783
23. Guerreiro R.J., Santana I., Bras J.M., Santiago B., Paiva A., and Oliveira C. Peripheral inflammatory cytokines as biomarkers in Alzheimer's disease and mild cognitive impairment. Neurodegener. Dis. 4 6 (2007) 406-412
24. Hashimoto Y., Chiba T., Yamada M., et al. Transforming growth factor beta2 is a neuronal death-inducing ligand for amyloid-beta precursor protein. Mol. Cell. Biol. 25 (2005) 9304-9317
25. Hashimoto Y., Nawa M., Chiba T., Aiso S., Nishimoto I., and Matsuoka M. Transforming growth factor beta2 autocrinally mediates neuronal cell death induced by amyloid-beta. J. Neurosci. Res. 83 (2006) 1039-1047
26. Hock C., Heese K., Müller-Spahn F., Huber P., Riesen W., Nitsch R.M., and Otten U. Increased CSF levels of nerve growth factor in patients with Alzheimer's disease. Neurology 54 (2000) 2009-2011
27. Humpel, C., Marksteiner, J. 2009. Peripheral biomarkers in dementia and Alzheimers disease. In: Michael S. Ritsner (Ed.), The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes, Volume III: Metabolic and Peripheral Biomarkers. Springer, ISBN: 978-1-4020-9837-6.
28. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat. Rev. Neurosci. 5 (2004) 347-360
29. Kaplin A., Carroll K.A., Cheng J., Allie R., Lyketsos C.G., Calabresi P., and Rosenberg P.B. IL-6 release by LPS-stimulated peripheral blood mononuclear cells as a potential biomarker in Alzheimer's disease. Int. Psychogeriatr. 21 2 (2009) 413-414 (Epub 2008 Dec 1)
30. Kassner S.S., Bonaterra G.A., Kaiser E., Hildebrandt W., Metz J., Schröder J., and Kinscherf R. Novel systemic markers for patients with Alzheimer disease? - a pilot study. Curr. Alzheimer Res. 5 4 (2008) 358-366
31. Komulainen P., Pedersen M., Hänninen T., Bruunsgaard H., Lakka T.A., Kivipelto M., Hassinen M., Rauramaa T.H., Pedersen B.K., and Rauramaa R. BDNF is a novel marker of cognitive function in ageing women: the DR's EXTRA Study. Neurobiol. Learn. Mem. 90 4 (2008) 596-603
32. Kong Q.L., Zhang J.M., Zhang Z.X., Ge P.J., Xu Y.J., Mi R.S., Zhao Y.H., Sui Y.P., and He W. Serum levels of macrophage colony stimulating factor in the patients with Alzheimer's disease. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 24 3 (2002) 298-301 (Chinese)
33. Levi-Montalcini R. The nerve growth factor, thirty-five years later. Biosci. Rep. 7 (1987) 681-699
34. Lim J.S., Cho H., Hong H.S., Kwon H., Mook-Jung I., and Kwon Y.K. Upregulation of amyloid precursor protein by platelet-derived growth factor in hippocampal precursor cells. Neuroreport 6 (2007) 1225-1229
35. Lindberg C., Chromek M., Ahrengart L., Brauner A., Schultzberg M., and Garlind A. Soluble interleukin-1 receptor type II, IL-18 and caspase-1 in mild cognitive impairment and severe Alzheimer's disease. Neurochem. Int. 46 7 (2005) 551-557
36. Lindahl B., Westling C., Gimenez-Gallego G., Lindahl U., and Salmivirta M. Common binding sites for beta-amyloid fibrils and fibroblast growth factor-2 in heparan sulfate from human cerebral cortex. J. Biol. Chem. 274 (1999) 30631-30635
37. Magaki S., Mueller C., Dickson C., and Kirsch W. Increased production of inflammatory cytokines in mild cognitive impairment. Exp. Gerontol. 42 (2006) 233-240
38. Malaguarnera L., Motta M., Di Rosa M., Anzaldi M., and Malaguarnera M. Interleukin-18 and transforming growth factor-beta 1 plasma levels in Alzheimer's disease and vascular dementia. Neuropathology 26 4 (2006) 307-312
39. Marksteiner, J., Georg Kemmler, Elisabeth M. Weiss, Gabriele Knaus, Celine Ullrich, Sergej Mechteriakov, Harald Oberbauer, Simone Auffinger, Josef Hinterhölzl, Hartmann Hinterhuber, and Christian Humpel. 2009 Apr 21. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging. [Epub ahead of print].
40. Marksteiner J., Pirchl M., Ullrich C., Oberbauer H., Blasko I., Lederer W., Hinterhuber H., and Humpel C. Analysis of cerebrospinal fluid of Alzheimer patients: biomarkers and toxic properties. Pharmacology 82 (2008) 214-220
41. Mocali A., Cedrola S., Della Malva N., Bontempelli M., Mitidieri V.A., Bavazzano A., Comolli R., Paoletti F., and La Porta C.A. Increased plasma levels of soluble CD40, together with the decrease of TGF beta1, as possible differential markers of Alzheimer disease. Exp. Gerontol. 39 10 (2004) 1555-1561
42. Moore A.H., and O'Banion M.K. Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease. Adv. Drug Deliv. Rev. 54 (2002) 1627-1656
43. Moser K., Reindl M., Blasig I., and Humpel C. Brain capillary endothelial cells proliferate in response to NGF, express NGF receptors and secrete NGF after inflammation. Brain Res. 1017 (2004) 53-60
44. Mufson E.J., Ma S.Y., Dills J., et al. Loss of basal forebrain p75NTR immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J. Comp. Neurol. 443 (2002) 136-153
45. Olson L., Nordberg A., von Holst H., Bäckman L., Ebendal T., Alafuzoff I., Amberla K., Hartvig P., Herlitz A., Lilja A., Lundqvist H., Långström B., Meyerson B., Persson A., Viitanen M., Winblad B., and Seiger A. Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient. J. Neural. Transm. 4 (1992) 79-95
46. Perry V.H., Bell M.D., Brown H.C., and Matyszak M.K. Inflammation in the nervous system. Curr. Opin. Neurobiol. 5 (1995) 636-641
47. Popp J., Bacher M., Kölsch H., Noelker C., Deuster O., Dodel R., and Jessen F. Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease. J. Psychiatr. Res. 43 (2009) 749-753
48. Ray S., Britschgi M., Herbert C., Takeda-Uchimura Y., Boxer A., Blennow K., Friedman L.F., Galasko D.R., Jutel M., Karydas A., et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 13 (2007) 1359-1362
49. Rodriguez-Rodriguez E., Sanchez-Juan P., Mateo I., Llorca J., Infante J., Garcia-Gorostiaga I., Berciano J., and Combarros O. Serum levels and genetic variation of TGF-beta1 are not associated with Alzheimer's disease. Acta Neurol. Scand. 116 6 (2007) 409-412
50. Sala G., Galimberti G., Canevari C., Raggi M.E., Isella V., Facheris M., Appollonio I., and Ferrarese C. Peripheral cytokine release in Alzheimer patients: correlation with disease severity. Neurobiol. Aging 24 7 (2003) 909-914
51. Schuitemaker A., Dik M.G., Veerhuis R., Scheltens P., Schoonenboom N.S., Hack C.E., Blankenstein M.A., and Jonker C. Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol. Aging 30 11 (2009) 1885-1889
52. Speciale L., Calabrese E., Saresella M., Tinelli C., Mariani C., Sanvito L., Longhi R., and Ferrante P. Lymphocyte subset patterns and cytokine production in Alzheimer's disease patients. Neurobiol. Aging 28 8 (2007) 1163-1169 (Epub 2006 Jun 30)
53. Tan Z.S., Beiser A.S., Vasan R.S., Roubenoff R., Dinarello C.A., Harris T.B., Benjamin E.J., Au R., Kiel D.P., Wolf P.A., and Seshadri S. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology 68 22 (2007) 1902-1908
54. Tarkowski E., Issa R., Sjögren M., et al. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol. Aging 23 (2002) 237-243
55. Thoenen H., and Barde Y.-A. Physiology of nerve growth factor. Physiol. Rev. 60 (1980) 1284-1335
56. Tsuboi Y., Kakimoto K., Nakajima M., Akatsu H., Yamamoto T., Ogawa K., Ohnishi T., Daikuhara Y., and Yamada T. Increased hepatocyte growth factor level in cerebrospinal fluid in Alzheimer's disease. Acta Neurol. Scand. 107 (2003) 81-86
57. Tuszynski M.H., Thal L., Pay M., Salmon D.P., Sang U.H., Bakay R., Patel P., Blesch A., Vahlsing M.L., Ho G., Tong G., Potkin S., Fallon J., Hansen L., Mufson E.J., Kordower J.H., Gall C., and Conner J. A phase I clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 11 (2005) 551-555
58. Zambrano N., Gianni D., Bruni P., Passaro F., Telese F., and Russo T. Fe65 is not involved in the platelet-derived growth factor-induced processing of Alzheimer's amyloid precursor protein, which activates its caspase-directed cleavage. J. Biol. Chem. 279 (2004) 16161-16169
59. Zetterberg H., Wahlund L.-O., and Blennow K. Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci. Lett. 352 (2003) 67-69
60. Zuliani G., Cavalieri M., Galvani M., Passaro A., Munari M.R., Bosi C., Zurlo A., and Fellin R. Markers of endothelial dysfunction in older subjects with late onset Alzheimer's disease or vascular dementia. J. Neurol. Sci. 272 1-2 (2008) 164-170